- Home
- SD vs KMDA Comparison
SD vs KMDA Comparison
Compare SD & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- KMDA
- Stock Information
- Founded
- SD 2006
- KMDA 1990
- Country
- SD United States
- KMDA Israel
- Employees
- SD N/A
- KMDA N/A
- Industry
- SD Oil & Gas Production
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- SD Energy
- KMDA Health Care
- Exchange
- SD Nasdaq
- KMDA Nasdaq
- Market Cap
- SD 465.2M
- KMDA 442.1M
- IPO Year
- SD 2007
- KMDA N/A
- Fundamental
- Price
- SD $12.21
- KMDA $7.46
- Analyst Decision
- SD
- KMDA Strong Buy
- Analyst Count
- SD 0
- KMDA 2
- Target Price
- SD N/A
- KMDA $14.50
- AVG Volume (30 Days)
- SD 221.1K
- KMDA 342.2K
- Earning Date
- SD 03-05-2025
- KMDA 03-05-2025
- Dividend Yield
- SD 3.60%
- KMDA N/A
- EPS Growth
- SD N/A
- KMDA 124.29
- EPS
- SD 1.27
- KMDA 0.27
- Revenue
- SD $120,243,000.00
- KMDA $158,380,000.00
- Revenue This Year
- SD N/A
- KMDA $15.37
- Revenue Next Year
- SD $43.19
- KMDA $8.58
- P/E Ratio
- SD $9.61
- KMDA $28.13
- Revenue Growth
- SD N/A
- KMDA 4.52
- 52 Week Low
- SD $10.31
- KMDA $4.74
- 52 Week High
- SD $15.31
- KMDA $9.15
- Technical
- Relative Strength Index (RSI)
- SD 52.32
- KMDA 52.89
- Support Level
- SD $11.95
- KMDA $7.51
- Resistance Level
- SD $12.59
- KMDA $8.35
- Average True Range (ATR)
- SD 0.30
- KMDA 0.41
- MACD
- SD 0.01
- KMDA -0.02
- Stochastic Oscillator
- SD 59.47
- KMDA 33.20
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.